|
1) Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001; 345: 517-25
|
|
|
|
2) Hetzel M, Bachem M, Anders D, et al. Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung. 2005; 183: 225-37
|
|
|
|
|
|
3) Maeda A, Hiyama K, Yamakido H, et al. Increased expression of platelet-derived growth factor A and insulin-like growth factor-I in BAL cells during the development of bleomycin-induced pulmonary fibrosis in mice. Chest. 1996; 109: 780-6
|
|
|
|
|
|
4) Lasky JA, Tonthat B, Liu JY, et al. Upregulation of the PDGF-alpha receptor precedes asbestos-induced lung fibrosis in rats. Am J Respir Crit Care Med. 1998; 157: 1652-7
|
|
|
|
|
|
5) Zhuo Y, Zhang J, Laboy M, et al. Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2004; 286: 182-8
|
|
|
|
|
|
6) Yoshida M, Sakuma J, Hayashi S, et al. A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene. Proc Natl Acad Sci U S A. 1995; 92: 9570-4
|
|
|
|
|
|
7) Yi ES, Lee H, Yin S, et al. Platelet-derived growth factor causes pulmonary cell proliferation and collagen deposition in vivo. Am J Pathol. 1996; 149: 539-48
|
|
|
|
|
|
8) Yoshida M, Sakuma-Mochizuki J, Abe K, et al. In vivo gene transfer of an extracellular domain of platelet-derived growth factor beta receptor by the HVJ-liposome method ameliorates bleomycin-induced pulmonary fibrosis. Biochem Biophys Res Commun. 1999; 265: 503-8
|
|
|
|
|
|
9) Aono Y, Nishioka Y, Inayama M, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med. 2005; 171: 1279-85
|
|
|
|
|
|
10) Azuma M, Nishioka Y, Aono Y, et al. Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med. 2007; 176: 1243-50
|
|
|
|
|
|
11) Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006; 173: 769-76
|
|
|
|
|
|
12) Thornton SC, Walsh BJ, Bennett S, et al. Both in vitro and in vivo irradiation are associated with induction of macrophage-derived fibroblast growth factors. Clin Exp Immunol. 1996; 103: 67-73
|
|
|
|
|
|
13) Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells. BMC Cancer. 2006; 6: 79-87
|
|
|
|
|
|
14) Abdollahi A, Li M, Ping G, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005; 201: 925-35
|
|
|
|
|
|
15) Simeone-Penney MC, Severgnini M, Rozo L, et al. PDGF-induced human airway smooth muscle cell proliferation requires STAT3 and the small GTPase Rac1. Am J Physiol Lung Cell Mol Physiol. 2008; 294: 698-704
|
|
|
|
|
|
16) Lewis CC, Chu HW, Westcott JY, et al. Airway fibroblasts exhibit a synthetic phenotype in severe asthma. J Allerg Clin Immunol. 2005; 115: 534-40
|
|
|
|
|
|
17) Baron R, Silverman ES, Grasemann H, et al. DNA sequence variants of the platelet-derived growth factor A-chain gene. Clin Exp Allergy. 2001; 31: 1501-8
|
|
|
|
|
|
18) Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005; 115: 2811-21
|
|
|
|
|
|
19) Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005; 353: 1412-3
|
|
|
|
|
|
20) Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008; 22: 1276-312
|
|
|
|
|
|
21) Nissen LJ, Cao R, Hedlund EM, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest. 2007; 117: 2766-77
|
|
|
|
|
|
22) Shikada Y, Yonemitsu Y, Koga T, et al. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res. 2005; 65: 7241-8
|
|
|
|
|
|
23) Shinohara ET, Gonzalez A, Massion PP, et al. PDGFR-Β expression in small cell lung cancer patients. Int J Radiat Oncol Biol Phys. 2007; 67: 431-7
|
|
|
|
|
|
24) Filiberti R, Marroni P, Neri M, et al. Serum PDGF-AB in pleural mesothelioma. Tumour Biol. 2005; 26: 221-6
|
|
|
|
|
|
25) Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-24
|
|
|
|
|
|
26) Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368: 1329-38
|
|
|
|
|
|
27) Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol. 2008; 26: 650-6
|
|
|
|
|
|
28) Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs. 2008; 9: 658-71
|
|
|
|
|